One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 op

The two NVX-CoV2373 boosters induced durable anti-SARS-CoV-2 immune responses up to 1 year after each dose and are therefore expected to persistently protect against SARS-CoV-2 infections and severe disease outcomes in Japanese adults. No new safety concerns were identified, demonstrating the expected acceptable safety profile in healthy Japanese participants.